Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
Top Cited Papers
- 4 June 2016
- journal article
- research article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 17 (7), 883-895
- https://doi.org/10.1016/s1470-2045(16)30098-5
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Phase II Trial of Temozolomide in Patients with Relapsed Sensitive or Refractory Small Cell Lung Cancer, with Assessment of Methylguanine-DNA Methyltransferase as a Potential BiomarkerClinical Cancer Research, 2012
- A German multicenter, randomized phase III trial comparing irinotecan–carboplatin with etoposide–carboplatin as first-line therapy for extensive-disease small-cell lung cancerAnnals of Oncology, 2011
- Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic AdenocarcinomaJournal of Immunotherapy, 2010
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaThe New England Journal of Medicine, 2010
- A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive diseaseAnnals of Oncology, 2010
- PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumorsProceedings of the National Academy of Sciences of the United States of America, 2010
- Treatment options for small cell lung cancer – do we have more choice?British Journal of Cancer, 2010
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Randomized Phase III Trial Comparing Irinotecan/Cisplatin With Etoposide/Cisplatin in Patients With Previously Untreated Extensive-Stage Disease Small-Cell Lung CancerJournal of Clinical Oncology, 2006
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989